Sam H. Whiting
Sam H. Whiting publishes mostly in Oncology, Cancer Research and Pulmonary and Respiratory Medicine, on topics such as Cancer, Lipids, and Metabolism, Pancreatic and Hepatic Oncology Research and Inflammatory mediators and NSAID effects.
- World rank
- #2,565,162 of 7,710,434 ranked researchers
- Rank in United States
- #753,789 of 1,627,098
- Works
- 81
- Citations
- 527
- Citations per work
- 6.5
What does Sam H. Whiting research?
Sam H. Whiting's work is mostly in Biochemistry, Genetics and Molecular Biology (32%), Medicine (25%), Immunology and Microbiology (7%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Life Sciences3239.1%
- Everything else2936.3%
- Health Sciences2024.6%
- Medicine2024.6%
- 1Oncology16% of their works
- 2Cancer Research14% of their works
- 3Pulmonary and Respiratory Medicine9% of their works
- 4Molecular Biology9% of their works
- 5Genetics8% of their works
- 6Immunology7% of their works
Research topics
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Inflammatory mediators and NSAID effects
- Cancer, Hypoxia, and Metabolism
- Estrogen and related hormone effects
- Peroxisome Proliferator-Activated Receptors
- Eicosanoids and Hypertension Pharmacology
- Colorectal Cancer Treatments and Studies
Which keywords describe Sam H. Whiting's research?
The keywords of their largest research topics: Inflammation, Cancer, Tumor Microenvironment, Chemotherapy, Nuclear Receptors, Transcriptional Regulation, Metabolism and Cyclooxygenase-2 Inhibitors.
- Epoxyeicosatrienoic Acids
- Arachidonic Acid
- Peroxisome Proliferator-Activated Receptors
- Estrogen
- HIF-1
- Prostaglandins
- Lipid Metabolism
- Cyclooxygenase-2 Inhibitors
- Transcriptional Regulation
- Chemotherapy
- Cancer
- Inflammation
- Tumor Microenvironment
- Nuclear Receptors
- Metabolism
- Fatty Acid Synthase
- Pancreatic Cancer
- Surgical Complications
- Warburg Effect
- PPARs
- Receptor
- Cetuximab
- KRAS Mutations
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Inflammation163 topics
- Cancer142 topics
- Tumor Microenvironment132 topics
- Chemotherapy112 topics
- Nuclear Receptors102 topics
- Transcriptional Regulation102 topics
- Metabolism92 topics
- Cyclooxygenase-2 Inhibitors71 topic
- Fatty Acid Synthase71 topic
- Lipid Metabolism71 topic
- Pancreatic Cancer71 topic
- Prostaglandins71 topic
- Surgical Complications71 topic
- HIF-161 topic
- Warburg Effect61 topic
- Estrogen51 topic
- PPARs51 topic
- Peroxisome Proliferator-Activated Receptors51 topic
- Receptor51 topic
- Arachidonic Acid41 topic
- Cetuximab41 topic
- Epoxyeicosatrienoic Acids41 topic
- KRAS Mutations41 topic
Where does Sam H. Whiting work?
Sam H. Whiting's main affiliation in the publication record is Tempest Technologies (United States), United States.
How many publications and citations does Sam H. Whiting have?
OpenAlex counts 81 works and 527 citations for Sam H. Whiting, an h-index of 10, ranking #2,565,162 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Sam H. Whiting. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.